Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 11/20 | 0.49 |
| ▸ | HTR2B | P41595 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 2/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13168280 | 0.90 | HTR6 (0.53) | HTR6HTR2BNPC1RAB9AHTR1A | |
| SCHEMBL3554577 | 0.86 | HTR6 (0.43) | CNR1HTR6HTR2BHTR1AHTR1D | |
| SCHEMBL4279205 | 0.85 | HTR6 (0.51) | HTR6HTR2BHTR1AHTR1D | |
| SCHEMBL3555577 | 0.81 | HTR6 (0.72) | HTR6HTR2BHTR1AHTR1D | |
| SCHEMBL3951219 | 0.80 | HTR6 (0.49) | HTR6HTR2BHTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL3549333 | 0.80 | HTR6 (0.72) | HTR6HTR2BHTR1AHTR1D | |
| SCHEMBL12622502 | 0.78 | HTR6 (0.47) | HTR6HTR2BHTR1AHTR1D | |
| SCHEMBL3947538 | 0.78 | HTR6 (0.47) | HTR6HTR2B | |
| SCHEMBL3558777 | 0.77 | HTR6 (0.73) | HTR6HTR2BHTR1AHTR1DITK | |
| Hydrochloric Acid SCHEMBL3549273 | 0.76 | HTR6 (0.73) | HTR6HTR2BHTR1AHTR1DITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790751-B2 | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790751-B2 | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790751-B2 | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1915348-A1 | AZINYL-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007032833-A1 | AZINYL-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007032833-A1 | AZINYL-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | HTR6, HTR1A, HTR3B | CNR1 49/4885ALDH1A1 1505/4885HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.